BT7

BT7 is a novel small molecule therapeutic being developed by Bycus Therapeutics for the treatment of oncology. As part of the company's early-stage pipeline of novel molecules, BT7 is categorized as a proprietary drug candidate targeting unspecified pathways in cancer biology. Bycus Therapeutics, a biotechnology company focused on developing innovative therapies for metabolic disorders, infectious diseases, and oncology, is currently advancing BT7 through preclinical development. Due to the early stage of the program, specific molecular targets and the exact mechanism of action have not yet been publicly disclosed.